

33rd Ordinary General Meeting of Shareholders

Sosei Group Corporation | 第33回定時株主総会

Disclaimer

The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the "Company") as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third party evaluation of any securities or any offering of them and should not be considered as a recommendation that any recipient should subscribe for or purchase any securities.

The information contained herein is in summary form and does not purport to be complete. Certain information has been obtained from public sources. No representation or warranty, either express or implied, by the Company is made as to the accuracy, fairness, or completeness of the information presented herein and no reliance should be placed on the accuracy, fairness, or completeness of such information. The Company takes no responsibility or liability to update the contents of this presentation in the light of new information and/or future events. In addition, the Company may alter, modify or otherwise change in any manner the contents of this presentation, in its own discretion without the obligation to notify any person of such revision or changes.

This presentation contains "forward-looking statements," as that term is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. The words "believe", "expect", "anticipate", "intend", "plan", "seeks", "estimates", "will" and "may" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. These factors include, without limitation, those discussed in our public reports filed with the Tokyo Stock Exchange and the Financial Services Agency of Japan. Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonably based on information currently available to the Company's management, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation and the company does not assume any obligations to update or revise any of these forward statements, even if new information becomes available in the future.

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Recipients of this presentation are not to construe the contents of this summary as legal, tax or investment advice and recipients should consult their own advisors in this regard.

This presentation and its contents are proprietary confidential information and may not be reproduced, published or otherwise disseminated in whole or in part without the Company's prior written consent. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This presentation contains non-GAAP financial measures. The non-GAAP financial measures contained in this presentation are not measures of financial performance calculated in accordance with IFRS and should not be considered as replacements or alternatives profit, or operating profit, as an indicator of operating performance or as replacements or alternatives to cash flow provided by operating activities or as a measure of liquidity (in each case, as determined in accordance with IFRS). Non-GAAP financial measures should be viewed in addition to, and not as a substitute for, analysis of the Company's results reported in accordance with IFRS.

References to "FY" in this presentation for periods prior to 1 January 2018 are to the 12-month periods commencing in each case on April 1 of the year indicated and ending on March 31 of the following year, and the 9 month period from April 1 2017 to December 31 2017. From January 1 2018 the Company changed its fiscal year to the 12-month period commencing in each case on January 1. References to "FY" in this presentation should be construed accordingly.

© Sosei Group Corporation. Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation. Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

Agenda

- 1 Opening Declaration
- 2 Report on number of voting rights
- 3 Audit Committee Report
- 4 Business Report & Audit Results
- 5 Business Outlook
- 6 Proposed Resolutions
- 7 Q&A
- 8 Vote
- 9 Closing Declaration



1

開会宣言
Opening Declaration



2

議決権個数のご報告
Report on the number of
voting rights



3


監査委員会の監査報告
Audit Committee Audit Report



4

2022年12月期の事業報告
連結業績
FY2022 Consolidated Results
Business Report

In 2022, we pursued strong revenue & cash generation combined with continued investment in R&D



¹ Upfront fee revenue recognised at deal inception

² Milestone revenue recognised at milestone event + deferred revenue releases

1

2022 Revenue of ¥15,569m (\$119m) vs. ¥17,712m (\$161m) in 2021. Decrease in upfront fee revenue partially offset by an increase in milestone income.

2

2022 Core Operating Profit of ¥5,856m (\$45m) vs. ¥8,904m (\$81m) in 2021. Reflects the decrease in Revenue and an increased Core R&D of ¥1,324m (\$2m), in line with our strategy.

3

2022 Net Profit of ¥383m (\$3m) vs. ¥1,017m (\$9m) in the 2021. Result impacted by a non-cash charge of ¥1,836m (\$14m) for impairment of the Group's investment in an associated company, MiNA.

4

¥67bn cash balance (\$507m) as at Dec 31, 2022. The majority is earmarked for acquisitions and in-licenses to accelerate our growth.

In 2022, we further enhanced the platform's value via multiple new collaborations...

Pre-Start / Discovery Updates

1

**WORLD-LEADING
DRUG DISCOVERY**



verily

New GPCR targets already identified with AI dataset



KALLYOPE

New platform to identify novel targets



Genentech
A Member of the Roche Group

5 milestones achieved across multiple programs



abbvie

New US\$1.2bn multi-target neurology collaboration
Received US\$10m milestone from Inflammatory collaboration



Lilly

New US\$700m multi-target Diabetes and Metabolic collaboration

... and saw excellent progress by our partners, including two new late-stage clinical trial starts

Translational Medicine / Clinical Development Updates

2

MAJOR CASH FLOW GENERATING PARTNERSHIPS



Strong **GLP-1** Ph. 1 data, **Ph. 2b** started H2 2022, received **US\$10m milestone**



M4 IND accepted by FDA and **Ph. 2** started H2 2022, received **US\$30m milestone**



mGlu₅ NAM received FDA clearance for Ph. 1 and **US\$5.3M grant from NIDA**

3

TRANSFORMING IN-HOUSE R&D



New **EP4** partnership to **maximize cancer trials**



M₁ ag. Japan Neurology

One new preclinical candidate – compound selected



Strategic collaboration to **drive R&D transformation and growth** and to **build Translational Medicine**

Our auditors intend to issue unqualified audit reports for FY2022

Ernst & Young ShinNihon LLC (EY) have audited the Consolidated Financial Statements and Parent Company Financial Statements for the full year ended December 31, 2022

- EY have indicated that they **intend to issue unqualified audit reports** thereon which will state that, in their opinion:

The **financial statements present fairly, in all material respects**, the consolidated financial position of the Group as at December 31, 2022, and its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRS).

The **non-consolidated financial statements present fairly, in all material respects**, the non-consolidated financial position of the Company as at December 31, 2022, and its non-consolidated financial performance for the year then ended in accordance with accounting principles generally accepted in Japan.

Management's report on the effectiveness of internal control over financial reporting, and its **conclusion that internal control over financial reporting was functioning effectively**, are appropriately stated.



Our Mission and Vision



MISSION

To invest in world-leading science and deliver life-changing medicines to patients



VISION

To become one of Japan's global biopharmaceutical champions

It has been a long road since our founding in 1990...



1990 - Founded by Chairman, **Shinichi Tamura**

1992 - ¥100m **Series A** financing

1994 - ¥400m **Series B** financing

90s

2005

Acquisition of **Arakis**, adding respiratory assets out-licensed to Novartis and launched in 2012



2004



IPO on Tokyo Stock Exchange Mothers (TSE:4565), raising over ¥11bn

2015




Acquisition of **Heptares Therapeutics**, adding a highly productive drug discovery platform



...to become a truly global biotech listed on TSE PRIME

TSE Market Segments



Business Performance and Financial Status

- Revenue > JPY 10bn and Market Cap > JPY 100bn



Liquidity thresholds – sufficient number of tradable shares and shareholders, and trading value



Governance – tradable share ratio maintained


8-MAR-23 TSE approved change of market listing segment from Growth Market to the Prime Market

15-MAR-23 Effective date of move to Prime Market


MAY-23 > Expected inclusion in TOPIX index

We have built a solid, diversified biotech company with a balanced pipeline of in-house and partnered programs...

PARTNERED



IN-HOUSE



...and we are implementing a clear and evolved strategy to accelerate growth and value creation into the future


(The graph is illustrative only)

Any of these four pillars could be further accelerated by opportunistic strategic actions, such as investments or M&A



2022

This year we will focus on delivering across the four strategic pillars to drive the business forward...



...and by 2030, our vision is to become one of Japan's global, fully integrated biopharmaceutical champions



Novel medicines on the market globally via partners

Commercial business in Japan

Broad and deep pipeline of programs

Sustainable financial performance

Leading biotech in Japan



5

連結計算書類の監査結果報告
Report on Audit Results on the
Consolidated Financial Statement



6

決議事項

Matters to be Resolved

Proposal No.1

Election of Nine (9) Directors

1	Shinichi Tamura	Chairman of the Board, Chair of the Nomination Committee, Member of the Compensation Committee	RE-APPOINTED		
2	Christopher Cargill	Director, Representative Executive Officer, President & CEO, Member of the Compensation Committee	RE-APPOINTED		
3	Tomohiro Toyama	External Director, Chair of the Audit Committee, Member of the Compensation Committee	RE-APPOINTED	EXTERNAL	INDIPENDENT
4	Kuniaki Kaga	External Director, Member of the Audit Committee	RE-APPOINTED	EXTERNAL	INDIPENDENT
5	David Roblin	External Director, Chair of the Compensation Committee, Member of the Nomination Committee	RE-APPOINTED	EXTERNAL	INDIPENDENT
6	Noriaki Nagai	External Director, Member of the Nomination Committee, Member of the Audit Committee	RE-APPOINTED	EXTERNAL	INDIPENDENT
7	Rolf Soderstrom	External Director, Member of the Audit Committee, Member of the Compensation Committee	RE-APPOINTED	EXTERNAL	INDIPENDENT
8	Miwa Seki	External Director, Member of the Audit Committee, Member of the Nomination Committee	RE-APPOINTED	EXTERNAL	INDIPENDENT
9	Eiko Tomita	—	NEWLY APPOINTED	EXTERNAL	INDIPENDENT

Note: Current positions and responsibilities at the Company are presented



7

質疑応答
Q&A



8

採決
Vote



9

閉会宣言
Closing Declaration

Locations

SOSEI HEPTARES

PMO Hanzomon 11F
2-1 Kojimachi, Chiyoda-ku
Tokyo 102-0083
Japan

Steinmetz Building
Granta Park, Cambridge
CB21 6DG
United Kingdom

North West House
119 Marylebone Road
London NW1 5PU
United Kingdom